Stay updated on Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial
Sign up to get notified when there's something new on the Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial page.

Latest updates to the Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial page
- Check5 days agoChange DetectedThe page’s release/version indicator was updated from Revision v3.5.2 to v3.5.3. This reflects a maintenance or deployment update rather than a change to study information.SummaryDifference0.0%

- Check12 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded detailed bone mineral density (BMD) Z-score change data at weeks 17, 41, 57, and 105 with race/age/gender standardization. Introduced summaries of participant satisfaction and product preference at Weeks 17 and 41, and removed older dated entries (2025-09 and 2025-10-10).SummaryDifference0.4%

- Check41 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing the previous v3.4.2.SummaryDifference0.0%

- Check77 days agoChange DetectedRevision: v3.4.2 is now shown on the page. The previous funding-status notice and Revision: v3.4.1 have been removed.SummaryDifference0.3%

Stay in the know with updates to Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial page.